Fig. 1From: Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept studyEffect of vupanorsen on ANGPTL3 (A), Triglyceride (B), and VLDL-C (C) levels in individual participants over the course of the study. Legend shows the patient number to link individual data from different figuresBack to article page